Permanent prostatic stent in the management of obstructive PePremramnaennetn ptr porsotastiact isct esntetn itn i nth teh me amnaangaegmeemnetn otf o ofb osbtrsutrcuticvteive Permanent prostatic stent in the management of obstructive prostate cancer in high-risk patients prporsotastea tcea cnacnecre irn i nh ihghig-hri-srkis kpa ptiaetnietnsts prostate cancer in high-risk patients Introduction Introduction : H. W. Gottfried H. HW. .W G.o Gttofrtitefdried H. W. Gottfried IntIrnotdruodctuicotnion

doi:10.3109/9780203427910-115

Chapter

Permanent prostatic stent in the management of obstructive PePremramnaennetn ptr porsotastiact isct esntetn itn i nth teh me amnaangaegmeemnetn otf o ofb osbtrsutrcuticvteive Permanent prostatic stent in the management of obstructive prostate cancer in high-risk patients prporsotastea tcea cnacnecre irn i nh ihghig-hri-srkis kpa ptiaetnietnsts prostate cancer in high-risk patients Introduction Introduction

Chapter

ABSTRACT

Introduction Prostatic carcinoma is the most common malignant tumour in men in the US and most European countries.1 At the time of diagnosis a considerable proportion of patients already have an advanced carcinoma with voiding difficulties.2,3 Furthermore, because of the patient’s advanced age, there are increasing numbers of patients who present serious surgical risks because of multiple concurrent diseases not related to the cancer. Ablative hormonal therapy is the classical mode of management for such patients:3-7 this form of treatment gives satisfactory results within 3 months in roughly two-thirds of all patients with bladder voiding disorders due to their carcinoma;8,9